Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

Gastroenterology - United Kingdom
doi 10.1053/j.gastro.2007.03.024
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Dietary Treatment of Active Crohn’s Disease

Nursing standard (Royal College of Nursing (Great Britain) : 1987)
Medicine
1990English

Certolizumab Pegol for the Treatment of Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2011English

Observer Agreement for Small Bowel Ultrasound in Crohn’s Disease: Results From the METRIC Trial

Abdominal Radiology
Nuclear MedicineRadiologyUrologyUltrasound TechnologyGastroenterologyRadiologicalImaging
2020English

Surgery for Intestinal Crohn’s Disease: Results of Multidisciplinary Approach

Turkish Journal of Surgery
2018English

Treatment Perspectives in Crohn’s Disease

Digestion
Gastroenterology
2018English

Randomised Clinical Trial: Certolizumab Pegol for Fistulas in Crohn’s Disease - Subgroup Results From a Placebo-Controlled Study

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2010English

Immunogenicity Negatively Influences the Outcome of Adalimumab Treatment in Crohn’s Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2008English

Randomised Trial of Mycophenolate Mofetil Versus Azathioprine for Treatment of Chronic Active Crohnʼs Disease

European Journal of Gastroenterology and Hepatology
HepatologyGastroenterology
1999English

Pgi21 - Cost-Effectiveness Analysis of Ustekinumab Versus Adalimumab, Infliximab and Vedolizumab for the Treatment of Patients With Moderately to Severe Active Crohn’s Disease for Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy